Portal fibrosis and hepatic steatosis in morbidly obese subjects

A spectrum of nonalcoholic fatty liver disease

Gary A. Abrams, Sachin S. Kunde, Audrey J Lazenby, Ronald H. Clements

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead to hepatic fibrosis and cirrhosis. Portal fibrosis in the absence of NASH, called isolated portal fibrosis (IPF), has received less attention and has not been classified as a spectrum of NAFLD. The aims of this study were to determine the prevalence of IPF in subjects undergoing gastric bypass surgery, to identify biochemical variables associated with IPF, and to assess the metabolic syndrome as defined by the Adult Treatment Panel III criteria. We analyzed liver biopsies from 195 morbidly obese subjects after excluding all other causes of liver disease. The prevalence of fatty liver (FL) only, IPF, and NASH was 30.3%, 33.3%, and 36.4%, respectively. Several biochemical parameters significantly trended across the 3 groups, with IPF falling between FL and NASH. Hyperglycemia was the only metabolic parameter associated with NASH (OR, 5.4; 95% CI, 2.4-12; P < .0001) and IPF (OR, 2.8; 95% CI, 1.2-6.5; P = .01). Subjects with diabetes had the greatest risk for NASH (OR, 8; 95% CI, 3.3-19.7; P < .0001) and IPF (OR, 4.3; 95% CI, 1.6-11.6; P = .003). The metabolic syndrome was identified in 78.5% of subjects, and a significant trend for the number of metabolic criteria was observed across the spectrum of FL, IPF, and NASH. In conclusion, a significant subset of morbidly obese individuals has portal fibrosis in the absence of NASH that is associated with glycemic dysregulation. Therefore, IPF should be considered a spectrum of NAFLD that may prelude NASH in morbid obesity.

Original languageEnglish (US)
Pages (from-to)475-483
Number of pages9
JournalHepatology
Volume40
Issue number2
DOIs
StatePublished - Aug 1 2004

Fingerprint

Fibrosis
Liver
Fatty Liver
Non-alcoholic Fatty Liver Disease
Gastric Bypass
Morbid Obesity
Hyperglycemia
Liver Cirrhosis
Liver Diseases
Biopsy

ASJC Scopus subject areas

  • Hepatology

Cite this

Portal fibrosis and hepatic steatosis in morbidly obese subjects : A spectrum of nonalcoholic fatty liver disease. / Abrams, Gary A.; Kunde, Sachin S.; Lazenby, Audrey J; Clements, Ronald H.

In: Hepatology, Vol. 40, No. 2, 01.08.2004, p. 475-483.

Research output: Contribution to journalArticle

Abrams, Gary A. ; Kunde, Sachin S. ; Lazenby, Audrey J ; Clements, Ronald H. / Portal fibrosis and hepatic steatosis in morbidly obese subjects : A spectrum of nonalcoholic fatty liver disease. In: Hepatology. 2004 ; Vol. 40, No. 2. pp. 475-483.
@article{5fd07d28f4774486af70ff3086432bc2,
title = "Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease",
abstract = "Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead to hepatic fibrosis and cirrhosis. Portal fibrosis in the absence of NASH, called isolated portal fibrosis (IPF), has received less attention and has not been classified as a spectrum of NAFLD. The aims of this study were to determine the prevalence of IPF in subjects undergoing gastric bypass surgery, to identify biochemical variables associated with IPF, and to assess the metabolic syndrome as defined by the Adult Treatment Panel III criteria. We analyzed liver biopsies from 195 morbidly obese subjects after excluding all other causes of liver disease. The prevalence of fatty liver (FL) only, IPF, and NASH was 30.3{\%}, 33.3{\%}, and 36.4{\%}, respectively. Several biochemical parameters significantly trended across the 3 groups, with IPF falling between FL and NASH. Hyperglycemia was the only metabolic parameter associated with NASH (OR, 5.4; 95{\%} CI, 2.4-12; P < .0001) and IPF (OR, 2.8; 95{\%} CI, 1.2-6.5; P = .01). Subjects with diabetes had the greatest risk for NASH (OR, 8; 95{\%} CI, 3.3-19.7; P < .0001) and IPF (OR, 4.3; 95{\%} CI, 1.6-11.6; P = .003). The metabolic syndrome was identified in 78.5{\%} of subjects, and a significant trend for the number of metabolic criteria was observed across the spectrum of FL, IPF, and NASH. In conclusion, a significant subset of morbidly obese individuals has portal fibrosis in the absence of NASH that is associated with glycemic dysregulation. Therefore, IPF should be considered a spectrum of NAFLD that may prelude NASH in morbid obesity.",
author = "Abrams, {Gary A.} and Kunde, {Sachin S.} and Lazenby, {Audrey J} and Clements, {Ronald H.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1002/hep.20323",
language = "English (US)",
volume = "40",
pages = "475--483",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Portal fibrosis and hepatic steatosis in morbidly obese subjects

T2 - A spectrum of nonalcoholic fatty liver disease

AU - Abrams, Gary A.

AU - Kunde, Sachin S.

AU - Lazenby, Audrey J

AU - Clements, Ronald H.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead to hepatic fibrosis and cirrhosis. Portal fibrosis in the absence of NASH, called isolated portal fibrosis (IPF), has received less attention and has not been classified as a spectrum of NAFLD. The aims of this study were to determine the prevalence of IPF in subjects undergoing gastric bypass surgery, to identify biochemical variables associated with IPF, and to assess the metabolic syndrome as defined by the Adult Treatment Panel III criteria. We analyzed liver biopsies from 195 morbidly obese subjects after excluding all other causes of liver disease. The prevalence of fatty liver (FL) only, IPF, and NASH was 30.3%, 33.3%, and 36.4%, respectively. Several biochemical parameters significantly trended across the 3 groups, with IPF falling between FL and NASH. Hyperglycemia was the only metabolic parameter associated with NASH (OR, 5.4; 95% CI, 2.4-12; P < .0001) and IPF (OR, 2.8; 95% CI, 1.2-6.5; P = .01). Subjects with diabetes had the greatest risk for NASH (OR, 8; 95% CI, 3.3-19.7; P < .0001) and IPF (OR, 4.3; 95% CI, 1.6-11.6; P = .003). The metabolic syndrome was identified in 78.5% of subjects, and a significant trend for the number of metabolic criteria was observed across the spectrum of FL, IPF, and NASH. In conclusion, a significant subset of morbidly obese individuals has portal fibrosis in the absence of NASH that is associated with glycemic dysregulation. Therefore, IPF should be considered a spectrum of NAFLD that may prelude NASH in morbid obesity.

AB - Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that can lead to hepatic fibrosis and cirrhosis. Portal fibrosis in the absence of NASH, called isolated portal fibrosis (IPF), has received less attention and has not been classified as a spectrum of NAFLD. The aims of this study were to determine the prevalence of IPF in subjects undergoing gastric bypass surgery, to identify biochemical variables associated with IPF, and to assess the metabolic syndrome as defined by the Adult Treatment Panel III criteria. We analyzed liver biopsies from 195 morbidly obese subjects after excluding all other causes of liver disease. The prevalence of fatty liver (FL) only, IPF, and NASH was 30.3%, 33.3%, and 36.4%, respectively. Several biochemical parameters significantly trended across the 3 groups, with IPF falling between FL and NASH. Hyperglycemia was the only metabolic parameter associated with NASH (OR, 5.4; 95% CI, 2.4-12; P < .0001) and IPF (OR, 2.8; 95% CI, 1.2-6.5; P = .01). Subjects with diabetes had the greatest risk for NASH (OR, 8; 95% CI, 3.3-19.7; P < .0001) and IPF (OR, 4.3; 95% CI, 1.6-11.6; P = .003). The metabolic syndrome was identified in 78.5% of subjects, and a significant trend for the number of metabolic criteria was observed across the spectrum of FL, IPF, and NASH. In conclusion, a significant subset of morbidly obese individuals has portal fibrosis in the absence of NASH that is associated with glycemic dysregulation. Therefore, IPF should be considered a spectrum of NAFLD that may prelude NASH in morbid obesity.

UR - http://www.scopus.com/inward/record.url?scp=4043132498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043132498&partnerID=8YFLogxK

U2 - 10.1002/hep.20323

DO - 10.1002/hep.20323

M3 - Article

VL - 40

SP - 475

EP - 483

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -